- Home
- BBT vs GRDN Comparison
BBT vs GRDN Comparison
Compare BBT & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBT
- GRDN
- Stock Information
- Founded
- BBT 1846
- GRDN 2004
- Country
- BBT United States
- GRDN United States
- Employees
- BBT N/A
- GRDN N/A
- Industry
- BBT Banks
- GRDN Retail-Drug Stores and Proprietary Stores
- Sector
- BBT Finance
- GRDN Consumer Staples
- Exchange
- BBT Nasdaq
- GRDN Nasdaq
- Market Cap
- BBT 2.0B
- GRDN 1.7B
- IPO Year
- BBT N/A
- GRDN 2024
- Fundamental
- Price
- BBT $24.52
- GRDN $28.28
- Analyst Decision
- BBT Buy
- GRDN Strong Buy
- Analyst Count
- BBT 2
- GRDN 3
- Target Price
- BBT $33.00
- GRDN $27.00
- AVG Volume (30 Days)
- BBT 847.3K
- GRDN 295.3K
- Earning Date
- BBT 10-29-2025
- GRDN 11-10-2025
- Dividend Yield
- BBT N/A
- GRDN N/A
- EPS Growth
- BBT N/A
- GRDN N/A
- EPS
- BBT 2.10
- GRDN N/A
- Revenue
- BBT $345,393,000.00
- GRDN $1,326,604,000.00
- Revenue This Year
- BBT $58.22
- GRDN $16.33
- Revenue Next Year
- BBT $61.27
- GRDN $2.10
- P/E Ratio
- BBT $11.72
- GRDN N/A
- Revenue Growth
- BBT 8.11
- GRDN 18.53
- 52 Week Low
- BBT $22.27
- GRDN $16.91
- 52 Week High
- BBT $32.36
- GRDN $30.39
- Technical
- Relative Strength Index (RSI)
- BBT N/A
- GRDN 71.35
- Support Level
- BBT N/A
- GRDN $23.72
- Resistance Level
- BBT N/A
- GRDN $24.86
- Average True Range (ATR)
- BBT 0.00
- GRDN 1.04
- MACD
- BBT 0.00
- GRDN 0.48
- Stochastic Oscillator
- BBT 0.00
- GRDN 90.32
About BBT Beacon Financial Corporation Common stock
Beacon Financial Corp operates as a multi-bank holding company. It offers commercial, business, and retail banking services, including a full complement of cash management products, online banking services, and consumer and residential loans.
About GRDN Guardian Pharmacy Services Inc. Class A Common Stock
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.